To better characterize therapeutic strategy, we retrospectively evaluated a multi-institutional cohort of BRAF-mutant NSCLC patients (n = 97) and an independent clinico-genomic database (n = 342), performed structural modeling, and conducted chemical screens of BRAF-mutant cell lines. Here, BRAF is linked to non-small cell lung carcinoma.